REPL$19.4810.62%1.87
After Hours: 19.51+0.03 +0.15%
Replimune Group Inc (REPL)
Date: 2026-11-02 16:00O: 17.75H: 19.68L: 17.67C: 19.49Vol: 7.725M
Replimune Group Inc stock is traded at $19.48, with a volume of 7,134,466. It is up +10.62% in the last 24 hours and up +49.04% over the past month. Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Previous Close:
$17.61
Open:
$17.75
24h Volume:
7,134,466
Relative Volume:
1.90
Market Cap:
$1.85B
Revenue:
-
Net Income/Loss:
-$313.94M
P/E Ratio:
-
EPS:
-$3.51
Net Cash Flow:
-$284.57M
1W Performance:
+56.21%
1M Performance:
+49.04%
6M Performance:
+679.20%
1Y Performance:
+100.21%
1-Day Range:
$17.67$19.68
1-Week Range:
$12.50$19.68
52-Week Range:
$1.50$19.68
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group IncSector
HealthcareIndustry
BiotechnologyPhone
(781) 222-9600Address
500 UNICORN PARK, WOBURN, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
Replimune Group Inc Stock (REPL) Financials Data
Replimune Group Inc Stock (REPL) Insider Trading
- Kapil DhingraNov 02 '26Director
- Transaction
- Proposed Sale
- Cost
- $17.75
- #Shares
- 16,500
- Value ($)
- 292,875
- #Shares Total
- 0
- VELEKA PEEPLES-DYEROct 30 '26Director
- Transaction
- Proposed Sale
- Cost
- $16.72
- #Shares
- 10,000
- Value ($)
- 167,232
- #Shares Total
- 0
- VELEKA PEEPLES-DYEROct 28 '26Director
- Transaction
- Proposed Sale
- Cost
- $12.90
- #Shares
- 12,000
- Value ($)
- 154,745
- #Shares Total
- 0
- Hill Emily LuisaAug 17 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $14.28
- #Shares
- 9,256
- Value ($)
- 132,176
- #Shares Total
- 215,852
- Hill Emily LuisaAug 10 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $12.97
- #Shares
- 11,448
- Value ($)
- 148,481
- #Shares Total
- 225,108
- Xynos KonstantinosAug 10 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $12.97
- #Shares
- 11,447
- Value ($)
- 148,468
- #Shares Total
- 224,215
- Schwendenman AndrewAug 10 '26Chief Accounting Officer
- Transaction
- Sale
- Cost
- $12.97
- #Shares
- 7,632
- Value ($)
- 98,987
- #Shares Total
- 99,425
- Patel SushilAug 10 '26Chief Executive Officer
- Transaction
- Sale
- Cost
- $12.97
- #Shares
- 39,341
- Value ($)
- 510,253
- #Shares Total
- 708,151
- Sarchi ChristopherJun 01 '26Chief Commercial Officer
- Transaction
- Sale
- Cost
- $9.24
- #Shares
- 12,000
- Value ($)
- 110,880
- #Shares Total
- 180,962
- Hill Emily LuisaMay 18 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $5.08
- #Shares
- 7,812
- Value ($)
- 39,685
- #Shares Total
- 236,556
